Eczema is not contagious, and is a chronic disease that causes symptoms of dry, itchy skin that can appear like a red rash, with some patients reporting a burning sensation, tingling or stinging.

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.

Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.Ruxolitinib ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

AbbVie (ABBV), a large drug maker, is jumping 8% after the company provided significantly higher-than-expected 2025 earnings ...

Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes ...

While many products are available for various skin needs, the foods you eat also have a major impact on the quality of your ...

The following is a summary of “A year in review: new treatments and expanded indications in dermatology in 2024,” published in the January 2025 issue of Dermatology by McGrath et al. In 2024, ...

Astria Therapeutics' focus on leveraging its half-life extension technology to create long-acting mAbs targeting derisked targets in established markets has positioned the company favorably in the ...

19. **Tarte Shape Tape Concealer**: Another concealer that’s worth all the buzz is Tarte’s Shape Tape Concealer. With its full coverage and matte finish, it’s the perfect solution for covering ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...